20:13 , May 30, 2017 |  BC Extra  |  Company News

Protagonist soars on Janssen IBD deal

Oral peptide therapeutic company Protagonist Therapeutics Inc. (NASDAQ:PTGX) jumped $3.60 (44%) to $11.82 on Tuesday after it granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to co-develop and co-promote...
07:00 , Oct 10, 2016 |  BioCentury  |  Finance

M&Allergan

Even after a two-month stretch that has seen Allergan plc (NYSE:AGN) acquire five biotechs and in-license a pharma asset, the company's gas tank is still nearly full. Allergan's bank account swelled to nearly $37 billion...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Allergan deal

The MedImmune LLC unit of AstraZeneca granted Allergan exclusive, worldwide rights to develop and commercialize MEDI2070 , a human mAb against IL-23. The candidate is in a Phase IIb trial to treat moderate to severe...
07:00 , Oct 3, 2016 |  BC Extra  |  Company News

AZ grants Allergan rights to anti-IL-23 mAb

The MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Allergan plc (NYSE:AGN) exclusive, worldwide rights to MEDI2070, a human mAb against interleukin-23 (IL-23). The candidate is in a Phase IIb trial to treat moderate...
07:00 , Apr 3, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer IL-23; CD40 Mouse studies suggest combination therapy with IL-23 and CD40 mAbs could be more effective at treating cancer than monotherapy. In a mouse...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Amgen, AstraZeneca deal

Amgen and AstraZeneca partnered to jointly develop and commercialize five of Amgen's human mAbs in its inflammation portfolio. The deal includes anti-IL17R mAb brodalumab (formerly AMG 827 ), which is slated to begin Phase III...
07:00 , Apr 9, 2012 |  BioCentury  |  Strategy

Divvying up skill sets

AstraZeneca plc 's deal for five clinical mAbs from Amgen Inc. 's inflammation and pulmonary portfolio puts the pharma close to its goal of getting 40% of its pipeline from external sources. For Amgen, last...
01:09 , Apr 3, 2012 |  BC Extra  |  Top Story

Amgen partners five mAbs with AZN

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to jointly develop and commercialize five of Amgen's mAbs in its inflammation portfolio. The deal includes anti- IL17R mAb brodalumab (formerly AMG 827 ), which is...